Futura Medical PLC
07 July 2026
7 July 2026
Futura Medical plc
("Futura", "the Group" or the "Company")
MED3000 (Eroxon®) European Patent No. EP 3934624B1 Opposition
Futura Medical announces that the European Patent Office ("EPO") Opposition Division has issued its written decision confirming the revocation of European Patent No. EP 3934624B1 for MED3000 (Eroxon®), following the Oral Hearing held on 8 May 2026.
The Company disagrees with the Opposition Division's decision, which it believes does not appropriately reflect fundamental principles of clinical research and development, and therefore intends to appeal the decision to the EPO Technical Board of Appeal. According to legal advice received by the Company, a full appeal process typically takes between 18 and 24 months, or longer, to conclude.
Importantly, the patent protection provided by EP 3934624B1 remains in force while the appeal is pending. The decision also does not affect the Company's existing commercial arrangements, the continued commercialisation of Eroxon®, or the Company's ability to continue supplying customers under those arrangements.
The decision relates solely to European Patent No. EP 3934624B1 and does not directly affect any other granted or pending patents within Futura's intellectual property portfolio including patents in other territories, the Company's European divisional patent application for MED3000, which is currently under examination, and separate patent filings relating to WSD4000, Futura's topical gel for the treatment of female sexual dysfunction.
Futura remains committed to protecting and defending its intellectual property portfolio globally and will continue to pursue all appropriate steps to safeguard its proprietary technologies.
Contacts:
|
Futura Medical plc |
Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO |
investor.relations@futuramedical.com +44 (0)1483 685 670 |
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) |
+44 (0)20 3100 2000 |
|
|
||
|
Turner Pope Investments (TPI) Ltd - Broker |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
||
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.